ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB – Get Free Report) was the target of a large drop in short interest during the month of October. As of October 31st, there was short interest totalling 7,600 shares, a drop of 54.8% from the October 15th total of 16,800 shares. Based on an average daily trading volume, of 11,400 shares, the days-to-cover ratio is presently 0.7 days.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in ProShares Ultra Nasdaq Biotechnology stock. Texas Capital Bank Wealth Management Services Inc purchased a new stake in ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB – Free Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 5,000 shares of the exchange traded fund’s stock, valued at approximately $288,000. Texas Capital Bank Wealth Management Services Inc owned about 0.31% of ProShares Ultra Nasdaq Biotechnology as of its most recent filing with the Securities and Exchange Commission.
ProShares Ultra Nasdaq Biotechnology Stock Performance
BIB traded up $0.16 on Wednesday, hitting $62.92. 7,485 shares of the company were exchanged, compared to its average volume of 23,601. ProShares Ultra Nasdaq Biotechnology has a 12 month low of $42.42 and a 12 month high of $69.56. The stock’s fifty day moving average is $63.82 and its 200-day moving average is $61.84.
ProShares Ultra Nasdaq Biotechnology Increases Dividend
ProShares Ultra Nasdaq Biotechnology Company Profile
ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period.
See Also
- Five stocks we like better than ProShares Ultra Nasdaq Biotechnology
- What Do S&P 500 Stocks Tell Investors About the Market?
- Rocket Lab is the Right Stock for the Right Time
- Following Congress Stock Trades
- SoundHound AI Will Advance By Triple Digits in 2025: Here’s Why
- What is a buyback in stocks? A comprehensive guide for investors
- Celsius Holdings: Big Drop, Big Opportunity? Analysts Say Yes
Receive News & Ratings for ProShares Ultra Nasdaq Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProShares Ultra Nasdaq Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.